The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The price increases are due to the rising costs of raw materials.
The jump in profit is due to the better performance of the API business.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
